Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

References

• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41–iv51.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–561.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–2388.
   PubMed Web of Science ®Google Scholar
• Breccia M, Colafigli G, Molica M, et al. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Expert Opin Drug Saf. 2016;15:525–533.
   PubMed Web of Science ®Google Scholar
• Zulbaran-Rojas A, Lin HK, Shi Q, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018;7:5457–5469.
   PubMed Web of Science ®Google Scholar
• Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35:626–630.
   PubMed Web of Science ®Google Scholar
• Kekale M, Soderlund T, Koskenvesa P, et al. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study. J Adv Nurs. 2016;72:2196–2206.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107:904–909.
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–5411.
   PubMed Web of Science ®Google Scholar
• Geissler J, Sharf G, Bombaci F, et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143:1167–1176.
   PubMed Web of Science ®Google Scholar
• Jonsson S, Olsson B, Soderberg J, et al. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann Hematol. 2012;91:679–685.
   PubMed Web of Science ®Google Scholar
• Unnikrishnan R, Veeraiah S, Mani S, et al. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib. Clin Lymphoma Myeloma Leuk. 2016;16:366–371.e3.
   PubMed Web of Science ®Google Scholar
• Lim YM, Eng WL, Chan HK. Understanding and challenges in taking tyrosine kinase inhibitors among Malaysian chronic myeloid leukemia patients: a qualitative study. Asian Pac J Cancer Prev. 2017;18:1925–1930.
   PubMedGoogle Scholar
• Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012;10:14–24.
   PubMedGoogle Scholar
• Boons CC, Timmers L, van Schoor NM, et al. Patient satisfaction with information on oral anticancer agent use. Cancer Med. 2018;7:219–228.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Easthall C, Willoughby KA, et al. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract. 2012;18:333–342.
   PubMedGoogle Scholar
• Ramesh A, Rajanandh MG, Thanmayee S, et al. Impact of patient counseling on medication adherence, beliefs and satisfaction about oral chemotherapies in patients with metastatic cancer at a super specialty hospital. Int J Cancer Res. 2015;11:128–135.
   Google Scholar
• Tan BK, Tan SB, Chen LC, et al. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adherence. 2017;11:1027–1034.
   PubMed Web of Science ®Google Scholar
• Boons CC, Swart EL, Timmers L, et al. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia. BMC Cancer. 2014;14:247.
   PubMed Web of Science ®Google Scholar
• Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10:135–140.
   PubMedGoogle Scholar
• Aaronson NK, Muller M, Essink-Bot M, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–1068.
   PubMed Web of Science ®Google Scholar
• Hurst NP, Ruta DA, Kind P. Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol. 1998;37:862–869.
   PubMedGoogle Scholar
• Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631–637.
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24.
   Web of Science ®Google Scholar
• Tibaldi G, Clatworthy J, Torchio E, et al. The utility of the Necessity–Concerns Framework in explaining treatment non-adherence in four chronic illness groups in Italy. Chronic Illn. 2009;5:129–133.
   PubMedGoogle Scholar
• Horne R. The Medication Adherence Report Scale (MARS): a new measurement tool for eliciting patients’ report non-adherence [Working paper]. Mayfield House (UK): University of Brighton; 2017.
   Google Scholar
• Cohen JL, Mann DM, Wisnivesky JP, et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol. 2009;103:325–331.
   PubMed Web of Science ®Google Scholar
• Mora PA, Berkowitz A, Contrada RJ, et al. Factor structure and longitudinal invariance of the Medical Adherence Report Scale-Asthma. Psychol Health. 2011;26:713–727.
   PubMed Web of Science ®Google Scholar
• Haque R, Shi J, Chung J, et al. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc (2003). 2017;57:303–310.e2.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen L, Guerin A, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin. 2013;29:1075–1082.
   PubMed Web of Science ®Google Scholar
• Rutten LJF, Arora NK, Bakos AD, et al. Information needs and sources of information among cancer patients: a systematic review of research (1980-2003). Patient Educ Couns. 2005;57:250–261.
   PubMed Web of Science ®Google Scholar
• Rood JA, Eeltink CM, van Zuuren FJ, et al. Perceived need for information of patients with haematological malignancies: a literature review. J Clin Nurs. 2015;24:353–369.
   PubMed Web of Science ®Google Scholar
• Faller H, Koch U, Brahler E, et al. Satisfaction with information and unmet information needs in men and women with cancer. J Cancer Surviv. 2016;10:62–70.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27:1511–1519.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671.
   PubMed Web of Science ®Google Scholar
• Verbrugghe M, Verhaeghe S, Lauwaert K, et al. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treat Rev. 2013;39:610–621.
   PubMed Web of Science ®Google Scholar
• Ross DM, Arthur C, Burbury K, et al. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Intern Med J. 2018;48: 5–13.
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CC, Verbrugghe M, et al. Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer. 2016;17:122.
   Web of Science ®Google Scholar
• European Public Assessment Report. Tasigna Product Information. European Medicines Agency (EMEA); 2018. Available from: http://www.ema.europa.eu.
   Google Scholar
• Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9:781–791.
   PubMed Web of Science ®Google Scholar